Almirall SA
OTC:LBTSF

Watchlist Manager
Almirall SA Logo
Almirall SA
OTC:LBTSF
Watchlist
Price: 15.47 USD Market Closed
Market Cap: 3.3B USD

Operating Margin
Almirall SA

7.1%
Current
5%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.1%
=
Operating Profit
113.5m
/
Revenue
1.6B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
ES
Almirall SA
MAD:ALM
2.8B EUR
7%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
499.6B USD
27%
CH
Roche Holding AG
SIX:ROG
263.4B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
213.2B GBP
24%
CH
Novartis AG
SIX:NOVN
211.1B CHF
33%
US
Merck & Co Inc
NYSE:MRK
265.6B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
212.8B USD
11%
US
Pfizer Inc
NYSE:PFE
142.7B USD
29%
No Stocks Found

Almirall SA
Glance View

Market Cap
3.3B USD
Industry
Pharmaceuticals

Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. Almirall's core strategy revolves around the development, manufacturing, and commercialization of its proprietary medications, particularly those targeting skin conditions such as psoriasis and atopic dermatitis. By investing heavily in research and development, Almirall ensures its pipeline remains robust with promising drug candidates and innovative therapies that can meet the unmet needs of dermatology patients. This focus gives them a strategic edge, allowing them to leverage their scientific expertise and deliver state-of-the-art solutions to the market. The financial health of Almirall thrives on a clear business model that involves both direct sales and strategic partnerships. Through collaborations with other pharmaceutical giants and dynamic distribution networks, the company expands its reach beyond Europe, tapping into the American and Asian markets as well. Licensing agreements and co-development partnerships are key to its financial strategy, effectively allowing Almirall to maximize its intellectual property while sharing risks and costs. This multi-pronged approach ensures a steady revenue stream from both its branded products and its generics division, which supplements the overall profitability and sustainability of the company. As Almirall continues to navigate the competitive landscape of the pharma industry, its resilience and adaptability underscore its enduring legacy.

LBTSF Intrinsic Value
16.45 USD
Undervaluation 6%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.1%
=
Operating Profit
113.5m
/
Revenue
1.6B
What is the Operating Margin of Almirall SA?

Based on Almirall SA's most recent financial statements, the company has Operating Margin of 7.1%.

Back to Top